Live feed09:00:00·1370dPRReleasevia QuantisnowDeciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022ByQuantisnow·Wall Street's wire, on your screen.DCPH· Deciphera Pharmaceuticals Inc.Health Care
